Loading
Annexon, Inc. Stock: price and insider trades · United States
1 insider bought €88k of shares over the last 90 days, the latest by Love Douglas, filed 25 Sept 2026.
Insider Decl.
169
Thresholds
n/a
Buy Volume
€52M
34 ops. · all time
Sell Volume
€3M
69 ops. · all time
Who traded when
BuySaleWilliam H. Carson10 buys
Muneer A. Satter6 buys
Jennifer Lew5 sales
Michael Overdorf5 sales
Ted Yednock5 sales
Dean Richard Artis3 sales
+3 other insiders
Since the insiders bought
- -30.8%Entry US$5.58 · Close 21 Oct 2026 US$3.86
- -12.6%Entry US$6.35 · Close at T+90 US$5.55
- +24.5%Entry US$4.49 · Close at T+90 US$5.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Annexon, Inc. Buy (bullish), based on 7 analysts. Average price target: US$17.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.83
Analyst consensus
7 analystsBuy
US$7.00Target US$17.00(+344%)US$27.00
Income statement
EBITDA-US$213.8M
Net income-US$206.7M0.0% margin
Valuation
PER (forward)-3.6x
P/Book3.6x
Beta1.33
Balance sheet & cash
Market capUS$726.1M
Total debtUS$26.2M
Free Cash Flow-US$186.5M
Debt / Equity13%
Profitability & ownership
ROE-105.3%
ROA-51.5%
% insiders0.4%
% institutions103.4%
Last declaration on 25 September 2026
Declarations169 total
26,065 shares@ US$3.830.014% mcap14.9% of flowCommon StockSEC:0001818520-26-000003:0
Canonical exit: 23 Dec 2026 (T+90)
2,000 shares@ US$5.2980.0015% mcap36.5% of flowCommonSEC144:0001959173-26-005993
2,000 shares@ US$6.3150.0018% mcap43.9% of flowCommonSEC144:0001959173-26-005238
1,000 shares@ US$5.6050.0008% mcap19.6% of flowCommonSEC144:0001959173-26-005219
30,646 sharesCommon StockSEC:0001818525-26-000004:0
613,497 shares@ US$5.410.33% mcap8.8% of flowCommon StockSEC:0001315797-26-000001:0
Canonical exit: 26 Aug 2026 (T+90)
8,000 shares@ US$6.200.0050% mcap14.6% of flowCommon StockSEC:0001824280-26-000003:0
Canonical exit: 9 Jul 2026 (T+90)
8,000 shares@ US$5.6713.5% of flowCommon StockSEC:0001824280-26-000002:0
Canonical exit: 8 Jun 2026 (T+90)
5,894 shares@ US$5.4341.5% of flowCommon StockSEC:0001958523-26-000003:0
5,820 shares@ US$5.4341.2% of flowCommon StockSEC:0001734424-26-000003:0
5,565 shares@ US$5.4216.1% of flowCommon StockSEC:0001465994-26-000003:0
4,339 shares@ US$5.4221.1% of flowCommon StockSEC:0001818522-26-000003:0
5,566 shares@ US$5.429.0% of flowCommon StockSEC:0001818525-26-000003:0
62,500 shares0Common StockSEC:0001958523-26-000002:0
62,500 shares0Common StockSEC:0001818525-26-000002:0
62,500 shares0Common StockSEC:0001818522-26-000002:0
56,250 shares0Common StockSEC:0001734424-26-000002:0
62,500 shares0Common StockSEC:0001465994-26-000002:0
5,290 shares@ US$5.1034.7% of flowCommon StockSEC:0001958523-26-000001:0
6,225 shares@ US$5.1028.2% of flowCommon StockSEC:0001818522-26-000001:0
5,290 shares@ US$5.1034.9% of flowCommon StockSEC:0001734424-26-000001:0
7,851 shares@ US$5.1121.2% of flowCommon StockSEC:0001465994-26-000001:0
7,857 shares@ US$5.1111.9% of flowCommon StockSEC:0001818525-26-000001:0
4,115 shares@ US$5.026.0% of flowCommon StockSEC:0001824280-26-000001:0
Canonical exit: 30 Mar 2026 (T+90)
4,115 shares@ US$4.475.5% of flowCommon StockSEC:0001824280-25-000007:0
Canonical exit: 1 Mar 2026 (T+90)
25 of 169 declarations
About Annexon, Inc.
On July 28, 2020, the day of Annexon's stock market listing, 5 insiders bought for EUR 16,711,615, including Bain Capital Life Sciences Investors, LLC (10% Owner) for EUR 5,802,644. Muneer A. Satter (Director) then bought EUR 16,756,195 on February 10, 2023 and EUR 9,265,945 on July 7, 2022. The file counts 35 purchases worth EUR 55.2 million (median EUR 42,425), against 69 sales worth EUR 2.71 million (median EUR 22,764), so 34% of open-market trades are purchases. The 34 purchases tracked to day 90 have a stored median of 18.7%, positive in 74% of cases (past results as stored, not a forecast).
Sales are modest: Ted Yednock (EVP & Chief Scientific Officer) sold EUR 274,129 on September 13, 2021, EUR 247,830 on March 25, 2021 and EUR 226,575 on June 3, 2021. Ted Yednock has 34 filings, 21 of them sales.
Read moreShow less
Douglas Love (PRESIDENT AND CEO) signs 29 filings, 2 purchases and 14 sales among them; Jennifer Lew (EVP & CHIEF FINANCIAL OFFICER) 26, William H. Carson (Director) 17, all purchases, and Michael Overdorf (EVP & CHIEF BUSINESS OFFICER) 17, 11 of them sales. 169 filings from 16 filers, with 41 in 2021 and 11 in 2022. The last twelve months: 32 filings, 13 purchases, 10 sales. Health care and pharma, USD 726.1 million, 0.4% held by insiders.
